Abstract
Background In women at high/intermediate lifetime risk of breast cancer (BC-LTR), contrast-enhanced magnetic resonance imaging (MRI) added to mammography ±ultrasound (Mx±US) increases sensitivity but decreases specificity. An alternative strategy, MRI alone, potentially more cost-effective, has never been explored. This study aims to assess the characteristics of women who participated in a randomized trial offering MRI alone.
Methods In this feasibility multicentre randomized controlled trial we compared MRI alone versus Mx+US in women at intermediate BC-risk (allocation ratio 1:1). Eligible women were aged 40 –59, with a 15–30% LTR and/or extremely dense breasts. Two screening rounds per woman were planned in ten centres experienced in MRI screening. Primary endpoint: rate of cancers detected in the two arms after 5 years of follow-up. Secondary endpoints: distribution of the risk profiles among the women enrolled in the trial; distribution of pathological stages and histology of cancers detected; interval cancer rate in the two arms.
Results From 07/2013 to 11/2015, 1,254 women (mean age 47 years) were enrolled: 624 were assigned to Mx+US, 630 to MRI. Most of them were aged below 50 (72%) and premenopausal (45%), 52% used oral contraceptives. Among postmenopausal women, 15% had used hormone replacement therapy. Breast and/or ovarian cancer in mother and/or sisters were reported by 37% of enrolled women, extreme breast density was recorded for 79%, 41% had a 15–30% BC-LTR.
Conclusions The distribution of BC-risk profile major determinants (breast density and family of breast and ovarian cancer) of enrolled women varied across centres.
Trial registration NCT02210546
Key points
Mammography plus ultrasound are commonly used to screen women with dense breasts
Supplemental ultrasound increases BC detection rate but also false-positives and potential overdiagnosis
Whether increased BC detection by US translates into reduced mortality is unknown
MRI alone could be more risk- and cost-effective than mammography plus ultrasound
Competing Interest Statement
Stefania Montemezzi declares to have received grants as a member of a medical advisory board for Leika and as speaker for Bayer. Simone Schiaffino declares to have received travel support from Bracco Imaging and to be member of speakers' bureau for General Electric Healthcare. Francesco Sardanelli declares to have received grants from or to be a member of speakers' bureau or advisory board for Bayer, Bracco, and General Electric. All other authors declare that they have no competing interests to disclose.
Clinical Trial
NCT02210546
Funding Statement
This study received funding from the Italian Ministry of Health through the "Ricerca Finalizzata" program (RF-2009-1539582). Bracco s.p.a. provided additional financial support and supplied contrast agent doses, without having any influence on the study planning phase or on patient recruitment, nor having any access to the study database.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of Regione Liguria for the coordinating centre and by the Ethics Committees of all participating centres. All enrolled women signed a written informed consent including a data publication section.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Dr. Stefano Corcione passed away on February 18, 2018
↵* Now at Department of Radiology, Grande Ospedale Metropolitano Niguarda, Piazza dell’Ospedale Maggiore 3, 20162, Milano, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, via Festa del Perdono 7, 20122 Milano, Italy
↵§ Now at Centro Mammografico, U.O. di Radiologia, Policlinico Sant’Orsola-Malpighi, Bologna, Italy
↵⁂ Now at Breast Imaging and Screening Unit, Department of Radiology, Humanitas Clinical and Research Center - IRCCS, Via Manzoni 56, 20089 Rozzano, Italy
Declarations
Ethics approval, consent to participate, consent for publication This study was approved by the Ethics Committee of Regione Liguria for the coordinating centre and by the Ethics Committees of all participating centres. All enrolled women signed a written informed consent including a data publication section.
Availability of data and material This article details the study design and characteristics of patients enrolled in the “MRIB” multicentre randomized controlled trial. All remaining study data will be the object of a separate publication.
Funding This study received funding from the Italian Ministry of Health through the “Ricerca Finalizzata” program (RF-2009-1539582). Bracco s.p.a. provided additional financial support and supplied contrast agent doses, without having any influence on the study planning phase or on patient recruitment, nor having any access to the study database.
Competing interests Stefania Montemezzi declares to have received grants as a member of a medical advisory board for Leika and as speaker for Bayer. Simone Schiaffino declares to have received travel support from Bracco Imaging and to be member of speakers’ bureau for General Electric Healthcare. Francesco Sardanelli declares to have received grants from or to be a member of speakers’ bureau or advisory board for Bayer, Bracco, and General Electric. All other authors declare that they have no competing interests to disclose.
L.A. Bonelli and F. Sardanelli performed statistical analysis.
All authors participated to manuscript drafting and reviewing
All authors read and approved the final manuscript.
Data Availability
This article details the study design and characteristics of patients enrolled in the "MRIB" multicentre randomized controlled trial. All remaining study data will be the object of a separate publication.
Abbreviations
- ACR
- American College of Radiology;
- BC
- breast cancer
- BD
- breast density;
- HRT
- postmenopausal hormone replacement therapy;
- MRI
- contrast-enhanced magnetic resonance imaging;
- Mx
- mammography;
- RCT
- randomized controlled trial
- US
- breast ultrasound.
